荣昌生物2025年净利7.09亿元，同比扭亏

Core Insights - Rongchang Biopharma (688331) reported a significant increase in revenue and a turnaround in net profit for the fiscal year 2025, with revenue reaching approximately 3.251 billion yuan, a year-on-year increase of 89.36%, and a net profit of about 709 million yuan, marking a return to profitability [1] Revenue Growth - The company's core products, Taitasip and Vidisicimab, experienced rapid growth in domestic sales, serving as the main drivers of revenue increase [1] - The successful collaboration with Vor Biopharma Inc. granted exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [1] Cost Management and Profitability - The company implemented management optimizations and production process iterations, which resulted in a reduction of unit production costs and an improvement in product gross margins [1] - A notable decrease in sales expense ratio contributed to the overall enhancement of profitability efficiency [1]